OptiNose, Inc. Stock News

YARDLEY, Pa., Dec. 26, 2024 (GLOBE NEWSWIRE) -- Optinose, Inc. (NASDAQ: OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that it will effect a 1-for-15 reverse stock split at 5:00 p.m. Eastern Standard Time, on December 30, 2024. Beginning with the opening of trading on December 31, 2024, Optinose's common stock w...

YARDLEY, Pa., Dec. 02, 2024 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that members of its management team will present a company overview and business update at the Piper Sandler 36th Annual Healthcare Conference on December 5, 2024 at 1:30 p.m. ET.

OptiNose, Inc. (NASDAQ:OPTN ) Q3 2024 Earnings Conference Call November 12, 2024 8:00 AM ET Company Participants Jonathan Neely - Vice President of Investor Relations and Business Development Ramy Mahmoud - Chief Executive Officer Terry Kohler - Chief Financial Officer Paul Spence - Chief Commercial Officer Conference Call Participants Thomas Flaten - Lake Street Capital Markets David Amsellem ...

Company reports Q3 2024 XHANCE net revenue of $20.4 million , an increase of 3% compared to Q3 2023

Conference Call and Webcast to be held November 12, 2024, at 8:00 a.m. Eastern Time Conference Call and Webcast to be held November 12, 2024, at 8:00 a.m. Eastern Time

YARDLEY, Pa., Oct. 16, 2024 (GLOBE NEWSWIRE) -- OptiNose, Inc. (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that the company has granted a non-qualified stock option awards to purchase an aggregate of 185,000 shares of its common stock to eight new employees as an inducement material for accepting empl...

YARDLEY, Pa., Oct. 07, 2024 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the appointment of Terry Kohler as Chief Financial Officer.

YARDLEY, Pa., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the peer-review publication of a paper titled, “EDS-FLU efficacy in patients with chronic rhinosinusitis with or without prior sinus surgery in ReOpen1 and ReOpen2 randomized controlled trials”1 in th...